Finance

Lists
ARQT:NASDAQ
Arcutis Biotherapeutics Inc
US$ २५.१७
+०.०४%
(+०.०१०) 1D
अक्टोबर ५, १४:३६:१९ GMT-४  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ARQT...
Open
US$ २५.०९
High
US$ २५.३८
Low
US$ २४.६९
Mkt. cap
३.१६ अरब
Avg. vol.
२९.०३ लाख
Volume
८.०६ लाख
P/E ratio
११७.३४
52-wk high
US$ ३१.७७
52-wk low
US$ १९.३०
EPS
US$ ०.२१
Beta
१.५७
Shares outstanding
१२.५७ करोड
No. of employees
३५४
Open
US$ २५.०९
High
US$ २५.३८
Low
US$ २४.६९
Mkt. cap
३.१६ अरब
Avg. vol.
२९.०३ लाख
Volume
८.०६ लाख
P/E ratio
११७.३४
52-wk high
US$ ३१.७७
52-wk low
US$ १९.३०
EPS
US$ ०.२१
Beta
१.५७
Shares outstanding
१२.५७ करोड
No. of employees
३५४
News stories
From web sources and news partners
Stock Traders Daily
Stock Traders Daily
·
५ घण्टा पहिले
Trading Systems Reacting to (ARQT) Volatility
About Arcutis Biotherapeutics Inc
CEOFrank Watanabe
Employees३५४
Founded२०१६
HeadquartersWestlake Village, क्यालिफोर्निया, संयुक्त राज्य अमेरिका
Sector-
Analyst ratings
Based on 6 analysts giving stock ratings to ARQT in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for ARQT in the last 3 months.
Highest
Current US$ २५.१७
US$ ४०.०० (+५८.९२%)
Average
US$ ३६.६७ (+४५.६९%)
Lowest
US$ ३४.०० (+३५.०८%)
Analyst
Recommendation
Action
Price target
Projected
Date
Douglas Tsao
H.C. Wainwright
Buy
Reiterated
US$ ३४.००
+३५.१%
08/10/2026
Judah Frommer
Morgan Stanley
Buy
Reiterated
US$ ३८.००
+५१%
08/06/2026
Serge Belanger
Needham
Buy
Reiterated
US$ ४०.००
+५८.९%
08/06/2026
Seamus Fernandez
Guggenheim
Buy
Reiterated
US$ ३८.००
+५१%
08/05/2026
Tyler Van Buren
TD Cowen
Buy
Maintained
US$ ३५.००
+३९.१%
08/05/2026
Uy Ear
Mizuho Securities
Buy
Reiterated
US$ ३६.००
+४३%
08/06/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
US$ ३५.००
+३९.१%
07/16/2026
Unknown Analyst
Jefferies
Buy
Maintained
US$ ३५.००
+३९.१%
07/09/2026
Richard Law CFA
Goldman Sachs
Hold
Maintained
US$ ३३.००
+३१.१%
02/27/2026
Last report
२०२६ अगस्ट ५
Fiscal period
Q2 2026
EPS / Est. (USD)
US$ ०.११ / US$ ०.०५
+१२०.००%beat
Revenue / Est. (USD)
१२.९९ करोड / ११.८९ करोड
+९.२६%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ सेप्टेम्बर
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
Revenue
९.९२ करोड
१२.९५ करोड
१०.५४ करोड
१२.९९ करोड
Cost of goods sold
८६.८५ लाख
१.१७ करोड
९७.८४ लाख
१.०९ करोड
Cost of revenue
८६.८५ लाख
१.१७ करोड
९७.८४ लाख
१.०९ करोड
Research and development expenses
१.९६ करोड
२.०५ करोड
३.०६ करोड
२.०४ करोड
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
६.२४ करोड
७.९० करोड
७.४१ करोड
८.२१ करोड
Operating expense
८.२० करोड
९.९४ करोड
१०.४७ करोड
१०.२५ करोड
Total operating expenses
९.०७ करोड
११.११ करोड
११.४५ करोड
११.३४ करोड
Operating income
८५.२६ लाख
१.८४ करोड
-९०.८९ लाख
१.६४ करोड
Other non operating income
-
४.४३ लाख
-२०.०० हजार
-१.५७ लाख
EBT including unusual items
७४.९० लाख
१.७९ करोड
-१.१२ करोड
१.५१ करोड
EBT excluding unusual items
७४.९० लाख
१.७९ करोड
-१.१२ करोड
१.५१ करोड
Income tax expense
८०.०० हजार
४.७० लाख
९३.०० हजार
१.३६ लाख
Effective tax rate
१.०७%
२.६३%
-०.८३%
०.९०%
Other operating expenses
-
-
-
-
Net income
७४.१० लाख
१.७४ करोड
-१.१३ करोड
१.५० करोड
Net profit margin
७.४७%
१३.४३%
-१०.७२%
११.५६%
Earnings per share
०.०६
०.१३
-०.०९
०.११
Interest and investment income
२०.३५ लाख
२०.३६ लाख
२२.७५ लाख
२२.७९ लाख
Interest expense
-३०.७१ लाख
-३०.०१ लाख
-४३.६८ लाख
-३४.०६ लाख
Net interest expenses
-१०.३६ लाख
-९.६५ लाख
-२०.९३ लाख
-११.२७ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
९०.८८ लाख
१.९० करोड
-८५.२७ लाख
१.७० करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google एपहरू